Visionary Holdings

GV

Market cap $1.23M

PALO ALTO, Calif.--(BUSINESS WIRE)--Odyssey, an AI lab pioneering world models founded by self-driving car veterans, today announced a $310 million Series B at a $1.45 billion valuation. Natural Capital led the round, with participation from Amazon, AMD Ventures, GV, EQT, IQT and others. They join existing investors including Jeff Dean, Google's chief scientist; Elad Gil; Qasar Younis, co-founder and CEO of Applied Intuition; Garry Tan, president and CEO of Y Combinator; Guillermo Rauch, founde.

Toronto, June 10, 2026 (GLOBE NEWSWIRE) -- On June 9, 2026, Visionary Holdings Inc. (the “Company”, Nasdaq ticker: GV) announced that on June 4, 2026, it received a Staff Determination Letter from the Nasdaq Listing Qualifications Department, in which Nasdaq regulatory staff formally determined to delist the Company's securities.

TORONTO, May 04, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (NASDAQ: GV) (the “Company” or “Visionary”) today announced that it received a staff determination letter from The Nasdaq Stock Market LLC (“Nasdaq”) on April 29, 2026, notifying the Company that it was not in compliance with Nasdaq Listing Rule 5250(f) due to delinquent listing fees and that Nasdaq had determined to delist the Company's securities unless the Company timely requested a hearing before the Nasdaq Hearings Panel.

TORONTO, April 10, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (NASDAQ: GV) (“Visionary” or the “Company”) today announced that it received a notification letter dated April 7, 2026 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), indicating that the Company is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market.

TORONTO, April 07, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (Nasdaq: GV) (the “Company”) today announced that it received a notification letter (the “Deficiency Letter”) from the Nasdaq Listing Qualifications Department on April 2, 2026, indicating that the Company is not in compliance with the continued listing requirements set forth in Nasdaq Listing Rule 5250(c)(1).

TORONTO, March 31, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (NASDAQ: GV) (“Visionary” or the “Company”) today announced that it has entered into an Investment Cooperation Agreement with Qingdao Xihai Rongke Enterprise Operation Management Co., Ltd. in connection with a proposed US$20 million strategic investment for the Company's Qingdao anti-aging project in Qingdao West Coast New Area, China.

The collaboration is expected to support the Company's commercialization efforts through access to an established offline service network The collaboration is expected to support the Company's commercialization efforts through access to an established offline service network

HONG KONG, March 09, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (NASDAQ: GV) (“the Company”), a technology-driven multinational enterprise focused on biotechnology and healthcare, today announced that its wholly owned subsidiary, Visionary Health Technology Group Limited (“GV Hong Kong”), has signed a US$12 million exclusive distribution agreement for its flagship anti-aging product, Premier Regenerative Complex-President Super Injection, in cooperation with Huajin China Investment Company（”Huajin China”), alongside the Board-approved divestiture of its non-core business. These strategic actions mark the Company's formal transition into a commercialization acceleration phase within the high-end medical aesthetics sector.

Company Continues Expansion into North America and Europe as Part of Global Medical Aesthetics Strategy Company Continues Expansion into North America and Europe as Part of Global Medical Aesthetics Strategy

HONG KONG, March 02, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (NASDAQ: GV) (“the Company”), a technology-driven multinational and biotechnology and healthcare-focused company, today announced that its wholly owned subsidiary, Visionary Health Technology Group Limited (“GV Hong Kong”), today announced the signing of a US$12 million exclusive distribution agreement for its flagship anti-aging product, Premier Regenerative Complex---President Super Injection, in cooperation with Huajin China Investment Company（”Huajin China”), alongside the Board-approved divestiture of its non-core education business.